- Home
- TDS vs TFX Comparison
TDS vs TFX Comparison
Compare TDS & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDS
- TFX
- Stock Information
- Founded
- TDS 1968
- TFX 1943
- Country
- TDS United States
- TFX United States
- Employees
- TDS N/A
- TFX N/A
- Industry
- TDS Telecommunications Equipment
- TFX Medical/Dental Instruments
- Sector
- TDS Telecommunications
- TFX Health Care
- Exchange
- TDS Nasdaq
- TFX Nasdaq
- Market Cap
- TDS 4.5B
- TFX 4.8B
- IPO Year
- TDS N/A
- TFX N/A
- Fundamental
- Price
- TDS $37.96
- TFX $111.21
- Analyst Decision
- TDS Buy
- TFX Hold
- Analyst Count
- TDS 2
- TFX 10
- Target Price
- TDS $52.00
- TFX $134.88
- AVG Volume (30 Days)
- TDS 813.0K
- TFX 697.9K
- Earning Date
- TDS 11-07-2025
- TFX 11-06-2025
- Dividend Yield
- TDS 0.42%
- TFX 1.23%
- EPS Growth
- TDS N/A
- TFX N/A
- EPS
- TDS N/A
- TFX N/A
- Revenue
- TDS $4,859,865,000.00
- TFX $3,189,988,000.00
- Revenue This Year
- TDS N/A
- TFX $10.42
- Revenue Next Year
- TDS $0.29
- TFX $10.58
- P/E Ratio
- TDS $79.50
- TFX N/A
- Revenue Growth
- TDS 110.05
- TFX 5.42
- 52 Week Low
- TDS $31.07
- TFX $102.58
- 52 Week High
- TDS $42.74
- TFX $195.42
- Technical
- Relative Strength Index (RSI)
- TDS 45.39
- TFX 43.95
- Support Level
- TDS $37.22
- TFX $104.21
- Resistance Level
- TDS $38.70
- TFX $108.56
- Average True Range (ATR)
- TDS 1.24
- TFX 4.90
- MACD
- TDS -0.09
- TFX -0.10
- Stochastic Oscillator
- TDS 50.48
- TFX 36.59
About TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.